Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refractory or Previously Untreated CLL
Status:
Terminated
Trial end date:
2019-09-25
Target enrollment:
Participant gender:
Summary
Combination study of monalizumab (IPH2201) with Ibrutinib in relapsed, refractory or
previously untreated Chronic Lymphocytic Leukemia (CLL) patients in 2 parts :
- phase 1 : a 3+3 design to assess the Maximum Tolerated Dose (MTD)
- phase 2: to evaluate the anti-leukemic activity of the combination